Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Rhea-AI Summary
Psyence BioMed (Nasdaq: PBM) reported results from its Annual and Special Meeting held Feb 12, 2026. Shareholders approved all matters, including election of directors, appointment of MNP LLP as auditors, and a special resolution authorizing the Board to implement one or more share consolidations up to 250:1.
All director nominees listed in the company's management information circular dated Jan 2, 2026 were elected to hold office until the next annual meeting. The Board will disclose final consolidation ratio and effective date if it decides to proceed, subject to regulatory and exchange approvals.
Positive
- All directors elected as listed in the Jan 2, 2026 management circular
- MNP LLP appointed as auditors for the ensuing year
- Share consolidation authority approved up to a 250:1 ratio
Negative
- Share consolidation up to 250:1 could materially reduce outstanding share count and affect trading liquidity
News Market Reaction – PBM
On the day this news was published, PBM declined 9.71%, reflecting a notable negative market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $324K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PBM gained 9.96% while only one tracked peer (GTBP) showed notable upside momentum and others were mixed, pointing to a stock-specific reaction rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Supply option agreement | Positive | +10.0% | Approved Put Option Agreement to secure long-term psilocybin and ibogaine supply. |
| Feb 11 | Litigation settlement | Neutral | -6.9% | Settled KAOS Capital shareholder claim with cash payment and share sale terms. |
| Jan 28 | Reverse stock split | Neutral | +22.0% | Announced effective date for 1-for-6.25 reverse stock split and share adjustment details. |
| Jan 22 | Meeting adjournment | Negative | -12.7% | Adjourned annual and special meeting due to failure to achieve quorum. |
| Jan 20 | Split postponement | Negative | -79.2% | Postponed previously announced 1-for-6.25 reverse stock split effective date. |
Recent news tied to capital structure and governance (reverse split, litigation, supply agreements) often coincided with large, directionally aligned price swings, both up and down.
Over the last month, PBM has focused on capital structure, litigation resolution, and governance. A 1-for-6.25 reverse split effective Feb 2, 2026 and related postponement drove sharp moves, including a -79.2% drop and a later 22.01% rise. The shareholder meeting was previously adjourned on Jan 22, 2026 for lack of quorum, then reconvened, while PBM also settled shareholder litigation and approved a Put Option Agreement to secure long-term psilocybin and ibogaine supply.
Market Pulse Summary
The stock moved -9.7% in the session following this news. A negative reaction despite routine approval outcomes would fit PBM’s history of sharp responses to capital-structure changes. Earlier announcements around the 1-for-6.25 reverse split and its postponement triggered moves of 22.01% and -79.2%. Granting the board authority for consolidations up to 250:1 could have revived concerns about future corporate actions, with sentiment influenced by prior volatility around similar decisions.
Key Terms
psilocybin medical
ibogaine medical
special resolution regulatory
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “Meeting”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “Board”).
All director nominees listed in the Company’s management information circular dated January 2, 2026 were duly elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Shareholders approved the appointment of MNP LLP as the Company’s auditors for the ensuing year and authorized the Board to fix the auditors’ remuneration. Shareholders further approved a special resolution authorizing the Board, in its sole discretion, to implement one or more consolidations of the Company’s issued and outstanding common shares, at a ratio of up to 250:1, with such consolidation(s) to be implemented, if at all, at a time and ratio to be determined by the Board.
The Company will provide additional disclosure if and when the Board determines to implement any share consolidation, including the final consolidation ratio and effective date, subject to applicable regulatory and exchange approvals.
Further details regarding the matters voted on at the Meeting are set out in the Company’s management information circular, which is available under the Company’s profile on EDGAR.
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the discretion of the Board to implement a share consolidation of the Company's issued and outstanding common shares. These statements are based on current assumptions and expectations, including assumptions regarding the Company’s ability to maintain compliance with Nasdaq’s continued listing standards. These assumptions may prove incorrect. There can be no assurance as to when a share consolidation will be implemented, if at all. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among others: (i) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (ii) potential volatility in the Company’s share price following the results of the Meeting; (iii) changes in the regulatory, competitive, and economic landscape; and (iv) risks associated with the Company’s development plans and clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
FAQ
What did Psyence BioMed (PBM) shareholders approve at the Feb 12, 2026 meeting?
Were the director nominees for Psyence BioMed (PBM) re-elected at the Feb 12, 2026 meeting?
What is the scope of the share consolidation authority approved for PBM on Feb 12, 2026?
Has Psyence BioMed (PBM) set an effective date or final ratio for the 250:1 consolidation?
Who will be the auditors for Psyence BioMed (PBM) for the coming year after the Feb 12, 2026 meeting?
Where can investors find more details about the matters voted on at the PBM meeting?
